<SEC-DOCUMENT>0001144204-13-012855.txt : 20130305
<SEC-HEADER>0001144204-13-012855.hdr.sgml : 20130305
<ACCEPTANCE-DATETIME>20130305101141
ACCESSION NUMBER:		0001144204-13-012855
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130301
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130305
DATE AS OF CHANGE:		20130305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS ONCOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		13664144

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS BIOTECHNOLOGY, INC.
		DATE OF NAME CHANGE:	20070220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v337098_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-underline-style: double">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt">FORM
8-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT PURSUANT TO SECTION 13
OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>March 1, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHAMPIONS ONCOLOGY, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 1in; text-align: left; font-weight: bold; border-bottom: Black 1pt solid; vertical-align: top"><B>Delaware</B></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid"><B>0-17263</B></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 1in; text-align: left; border-bottom: Black 1pt solid; vertical-align: top"><B>52-1401755</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 1in; text-align: left; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(State or Other Jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">of Incorporation)</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 1in; text-align: left; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1 University Plaza, Suite 307, Hackensack,
New Jersey 07601</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (<B>201) 808 8400</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not Applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address if Changed
Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION TO BE INCLUDED IN THE REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1.25in; text-align: left"><B>Item 5.02.</B></TD><TD STYLE="text-align: justify"><B>Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">On
March 1, 2013, the Company&rsquo;s board of directors increased the size of the board from six to eight directors. Pursuant to
the Company&rsquo;s bylaws, the board of directors appointed two new directors, Daniel Mendelson and <FONT STYLE="color: #343434">Arthur
G. Epker, III</FONT>, to fill the vacancies created by the increase in the size of the board.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0; text-indent: 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Mr. Epker is Vice President and partner
of PAR Capital Management, Inc. (&ldquo;<B>PAR Capital</B>&rdquo;), an investment adviser that manages PAR Investment Partners,
L.P. (&ldquo;<B>PAR Investment Partners</B>&rdquo;), a private investment fund. Pursuant to the terms of the Securities Purchase
Agreement dated January 28, 2013, entered into among the Company, PAR Investment Partners and other parties (the &ldquo;<B>Securities
Purchase Agreement</B>&rdquo;), PAR Investment Partners purchased 10,000,000 shares of the Company&rsquo;s Common Stock at a purchase
price of $0.50 per share for a purchase price of $5,000,000. In addition, PAR Investment Partners received a warrant to purchase,
until January 28, 2018, an aggregate of 1,000,000 additional shares of Common Stock at an exercise price of $0.66 per share. The
Securities Purchase Agreement contains certain registration rights with respect to the shares of Common Stock issued to PAR Investment
Partners and the shares of Common Stock issuable upon exercise of the warrant granted to PAR Investment Partners. Furthermore,
PAR Investment Partners has the right to require the Company to repurchase the purchased shares (the &ldquo;<B>Put Option</B>&rdquo;)
for cash for $0.50 per share upon<FONT STYLE="color: black"> a change of control or sale or exclusive license of substantially
all of the Company&rsquo;s assets</FONT>. The Put Option will terminate upon the achievement of certain financial milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">As a Vice President and partner of PAR
Capital, and PAR Capital&rsquo;s role as advisor to PAR Investment Partners, Mr Epker has an indirect beneficial ownership of the
shares held by PAR Investment Partners but disclaims beneficial ownership except to the extent of his pecuniary interest therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Pursuant to the terms of the Securities
Purchase Agreement, the Company agreed to appoint one nominee nominated by PAR Investment Partners to become a member of the Company&rsquo;s
board of directors. Mr. Epker was appointed to the board in accordance with the terms of the Securities Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Also on March 1, 2013,
Ana Stancic, a director of Champions Oncology, Inc. (the &ldquo;<B>Company</B>&rdquo;) and chair of the Company&rsquo;s audit
committee, resigned from the Company&rsquo;s board of directors. Ms. Stancic informed the Company that her resignation was not
related to any disagreement with the Company. The board of directors vested Ms. Stancic&rsquo;s unvested options and restricted
stock and amended Ms. Stancic&rsquo;s options to extend the exercisability period from the original term, which terminated 90
days after Ms. Stancic&rsquo;s resignation, until the end of the full term of those options, notwithstanding her resignation.
The board appointed one of the Company&rsquo;s directors, Scott Tobin, to replace Ms. Stancic as chair of the Company&rsquo;s
audit committee.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding-left: 0.5in"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; font-weight: bold"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company&rsquo;s
press release describing the events referenced above is attached hereto as Exhibit 99.1.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 1.25in; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(d)&#9;Exhibits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">The following
exhibits are filed herewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><U>Exhibit
No.</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left">99.1</TD><TD STYLE="text-align: justify">Press release dated March 5, 2013</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding-left: 0.5in"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; font-weight: bold"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3"><B>CHAMPIONS ONCOLOGY, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">(Registrant)&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Date: March 5, 2013</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 23%; border-bottom: Black 1pt solid">/s/ Joel Ackerman</TD>
    <TD STYLE="vertical-align: top; width: 23%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joel
Ackerman <BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v337098_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Arial, Helvetica, Sans-Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="height: 1in">
    <TD STYLE="width: 50%; border-bottom: Black 2pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><IMG SRC="image_001.jpg" ALT="">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; text-align: right; vertical-align: bottom; border-bottom: Black 2pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">NEWS</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">One University Plaza, Suite
    307 Hackensack, NJ 07601 Tel: 201-808-8400</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #00000A"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">For
Immediate Release</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7DABC3"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7DABC3"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; color: #107FC5"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Champions
Oncology Reports Changes to Board of Directors </B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; color: #107FC5"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; color: #343434">Hackensack,
NJ &ndash; March 5, 2013 Champions Oncology, Inc. (OTC: CSBR) is pleased to announce the appointments of Dan Mendelson and Arthur
G. (&ldquo;Bart&rdquo;) Epker, III to the Board of Directors of </FONT>Champions Oncology, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Dan
Mendelson is CEO and founder of Avalere Health, a strategic advisory company focused on devising innovative solutions to complex
healthcare problems. The firm's customer base includes Fortune 500 healthcare companies, provider organizations, medical foundations,
and government. Dan is also currently Adjunct Professor of Business Administration at The Fuqua School of Business at Duke University
and sits on the boards of Coventry Health Care Inc. and HMS Holdings Corp. From 1998 to 2000, Dan served as Associate Director
for Health at the Office of Management and Budget (OMB). Prior to joining OMB, Dan was Senior Vice President of The Lewin Group
and Director of the Medical Technology practice. He holds an undergraduate degree in economics and viola performance from Oberlin
College, and a M.P.P. from the Kennedy School of Government at Harvard University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Bart
Epker is a Vice President and partner of PAR Capital Management, Inc., an investment adviser that manages PAR Investment Partners,
L.P., a private investment fund. Bart is a member of the boards of directors of Pure Cycle Corporation, the Steppingstone Foundation,
and the Winsor School and is on the Honors Alumni Council at the University of Michigan. Prior to joining PAR Capital in 1992,
Bart worked at TA Associates, a private equity firm. He received his undergraduate degree in computer science and economics with
highest distinction from the University of Michigan (1983) and his Masters of Business Administration from Harvard Business School
(1987).<FONT STYLE="color: #18376A"> </FONT>PAR Investment Partners purchased common stock and warrants of the Company in a private
placement on January 28, 2013. As part of that transaction, the Company agreed to appoint a designee of PAR Investment Partners,
to its board of directors. Bart is the designee chosen by PAR Investment Partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Dr.
David Sidransky, Chairman of the Board of Directors, commented, &ldquo;The addition of such outstanding directors like Dan and
Bart is an important milestone in the continued evolution of Champions to meet the market needs. We are excited to be welcoming
them to the board and look forward to their guidance through the continued strategic, operational and financial growth of the
company.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">In
conjunction with these appointments, Ana Stancic has resigned from the Board of Directors. Scott Tobin, a current director of
the company, will assume the role of Chairman of the Audit Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Dr.
David Sidransky, Chairman of the Board of Directors commented, &ldquo;We thank Ana for the years of service she provided the company.
Her insights and experience have helped set the strategic direction and ensured financial discipline at the company.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"></FONT></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;&nbsp;<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding-left: 0.5in"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; font-weight: bold"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Ana
Stancic commented, &ldquo;It has been very rewarding to contribute to the progress the company has made during my board tenure.
I look forward to watching the company progress in the future from the solid foundation that has been built over time.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>About
Champions Oncology, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Champions
Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and
use of oncology drugs. The Company&rsquo;s TumorGraft Technology Platform is a novel approach to personalizing cancer care based
upon the implantation of primary human tumors in immune deficient mice followed by propagation of the TumorGrafts in a manner
that preserves the biological characteristics in order to determine the efficacy of a treatment regimen. The Company uses this
technology to offer solutions for Personalized Oncology Solutions, which guides the development of personalized treatment plans,
and Translational Oncology Solutions, which assists pharmaceutical and biotechnology companies seeking personalized approaches
to drug development to lower the cost and increase the speed of drug development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">For
more information, visit www.championsoncology.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">This
press release may contain &quot;forward-looking statements&quot; (within the meaning of the Private Securities Litigation Act
of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as &quot;believe,&quot;
&quot;may,&quot; &quot;could,&quot; &quot;will,&quot; &quot;intend,&quot; &quot;expect,&quot; &quot;anticipate,&quot; &quot;plan,&quot;
and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements.
The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen
factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2012 for a discussion of such risks, uncertainties
and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable,
they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of
activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking
statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's
expectations, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!1`/(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MK(\0>(K;0;8-)^\G<?NX0>6]SZ"JC%S?+'<B=2-.+E)V1J22)$A>1U1!R68X
M`K#N_&NBVC%?M)F8=H5+?KTKSK5M<OM:F+W<Q*9^6)>$7\*SJ].GERM>H_N/
M$K9O*]J2^\]'/Q&TW=@6UT1ZX7_&K=KXZT:Y8*\TD!/_`#U0@?F,UY;16KR^
MD]KG/'-JZ>MF>X07$-U$)+>5)8ST9&!%2UXKI^IWFE3B6RG:)NX'W6^HZ&O2
M/#7BV#6U$$X6&]4<IGA_=?\`"N&O@Y4ES+5'JX7,85WRRT9T5%%%<9Z(4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`%'6-4B
MT?3);N;D(,*O]YCT%>07]]/J5[)=73EI9#D^@'8#VKJ?B)J)EU&&P4_)`N]A
MZL>GZ?SKCJ]K`T5"'.]V?-9IB74J>S6R_,*Z+2?!6I:I&LKA;6%N0TH.YA[+
M_C6IX'\-)<*-4O4#(#^X1AP2/XC_`$KOJSQ.-<)<E,UP66JI%5*NSV1Q`^&L
M6SYM1?=[1#'\ZR]2\`ZC9QF2T=+M1SM4;7_+O7HDM]:P2;);F%'_`+K.`:F5
M@R@J00>A'>N...JI[W/0EEN&DK)6^9X:597*LI#`X*D<@^F*]!\'^$3:;-1U
M%/W_`%BB/_+/W/O_`"KH9=`T^;5DU%[=3<H.#V)[$CN1ZUHUK7QKJ1Y8Z=S'
M"98J4W.;O;86BDHK@/6%HI*6@`HI*6@`HI**`%HI**`%HI**`%HHI*`%HI**
M`%HI**`%HHHH`****`"BBB@#Q_Q/*9O$U^Q/24J/H./Z5E@$D`=3P*T_$L9B
M\2:@I_Y[$_GS_6LP':0PZ@YKZ2E_#5NQ\96_BROW9[98VRV=A!;H,+%&J#\!
M63XMU:32]+46[;9IVV*W]T=R/>MFUG6YM(ID.5D0,#]16'XRTR74-+22!2\E
MNV_:.I4CG%?,5N;E=MSZV=U2]SL>=L2[%F)9CR2>2:Z/P=K$UKJ<=D[EK><X
M"DYVMV(KG*W_``?IDMYJ\=UM(@MSN+]BW8"O-HWYU8\ZCS>T7*>BUQ4^M:QX
MBU>>ST*1;>V@.&F/4\XSG^0%=JPRI'K7`>&M1B\+ZM?Z=JI,.]P5D(..,X_`
M@]:]_#Q34I)7:V1TXN34H1;M%[O\M3:T6#Q)::IY&HS17-GM),IZY[`=#GZU
M'-JMXGQ`CL/M!%H8\F/`QG:3UK1M?%6F7NJ+86LQED=20ZJ=I([9KF-<TV/5
MOB$MG*[QI)$,LG484FKIKFF_:*VCZ?B959<E./LI<WO+K^%S6\9:M=Z<^G"Q
MN#'YLA#[<'(X_P`:ZAF"*68@*!DD]J\U\2>&X-`FL&@GFE,TN#YF.,$>GUKJ
MO&VIFPT)H8S^^NSY2@=<=_TX_&E.E&2IQAUOJ.G7E&56=32UM+WZ?J<_:>+K
MU_$:7$LCC2IIS"JD#:!T!SZ\@_C7>W#%+:5E."$)!_"O.+C1M?'A];&338EM
MX"9MZL-^>23UKKO#^J_VMX5$K-F6.-HY/J!U_$8-5B:<;*4+66FGX$8.M.\H
M5+W:OK^*.?\`"7BZZFU+[+JLYD2?B-V`&UO3CUJ/4O%]Y<>)8X=/N#'9K,L7
M`!\SYN3FJ^AZ#_;OA&X$(47<-P6B8\9^494GT-2ZWI,>BS>'[6/!82;I'_O,
M67)KHY:/M6DM=K?J<BGB?8)MZ:._75VL;WCC5+S2[&U>QG:%WE*L0`<C'O65
M?77BCP];QWUU>0W5N6`9,#O^`/Y5:^)'_(-LO^NQ_P#0333X3UC55B35M7$E
MJI#;$'/\@/QK&ER1I1<K6UOH=-?VDJ\XPO=6M9Z+U+GBK6KB#PQ;7^GRM"TS
M(<@`G!4G'-:5YK"Z7X<2_N/G;RD('3>Q`X_.L?Q]$EOX7@AB&U(Y451Z`*:E
M\26$NH>"85@4L\4<<NT=2`O/Z&LXP@XPOLVS:52I&=2VK45]^IGVJ>+-<MQ?
MQ7L=K&_S11],C\CQ]:T?#/B*ZN[V;2M60)?0Y(8#&\#KGW^G6FZ#XOTO^Q8$
MNKA;>:",(R,#S@8R/6J'A]FUSQM<ZO#&R6L:E0Q&-QQM`^O>M)1;4U.-DMM/
MZN90FHRING-R;W5[^OI83Q!XGOM'\6E$D+VB!"T.!@@CGGUJ]XMUZ:'0[*]T
MFY*+/)]]0#D8/'-4[JVBO/B6]O<('BDMRK*>XV5SOB"QN]#<Z7(Q>S,GGP,>
M_&/Z\BM*=.G)P5M;)^IC5K5H1J.^C;7H_P#([SQ/K4^C:`MQ;@&>0JBLPR%)
M&<X_"LBRA\4LEO=V^IVUY'*5+H2"%!]>.WM6SX@NM-M]"C75T:2"7:@51DY]
M1Z8ZUQ&I1Z=I*QWGA[6)&F+C]R"<@>_3\C65"*E"R6K>[5U_P#;%3<:G,Y:)
M+1.S7RZGJ0SCGK2U#9O)+9P/,NV5HU+KZ$CFIJX'H>JG=7"BBB@84444`>;?
M$'3S;ZS'=J/W=RF"?]I>/Y8KDZ]B\0:.FMZ5);,0L@^:)C_"PZ?X5Y#<6\MK
M<203H4EC.UE/8U[>!K*=/EZH^8S/#NG5<UM([SP)XA22V72KEPLL?^H)_B7^
M[]1_*NTKPQ69&#(2K`Y!!P0:Z[2?B#=6L:Q:C#]J4<"13M?\>QK#%8*3EST_
MN.O`YE&,53J].IV\^B:=<S>;-90.YY+%.M7(HHX8Q'$BHB]%48`KEQ\0]**9
M,5T#Z;!_C67J7Q%DDC*:;:^63_RTE()'T`KCA@JK>D;'=+'8:"YE+[CMWOK:
M.]2T>=!<NI98R>2*CO\`2;'4U47MK'-MZ%AR/QZUXY)=W$MV;J2:1K@MN\PM
M\V?7->C^%/%B:M&MI>,J7JC@]!*/4>_M6U;!SHI3B_4QP^84\1)TYJU]O,V[
M#2+#3-WV*UCA+=2HY/X]:<=,LVU`7QMT-T!@2]\8Q5JEKC<I-WN>BJ<4K):%
M2]TRSU$QF\MTF,1RF[^$U'J-GITA2[U&.$_9^5DDZ)SFK]8WB.VEFBM)DA:X
MBMYQ)+"HR77Z=\>E3*<HJZZ"G&-F[7+UGJ5GJ*L;2XCF"\,%/3ZBJED-&L;&
M:>S\B*UD;;(R'Y2>F#^=5+,'4/$27UM:RV]O'`8W>2/8923P,=\>M81TF^M]
M#62WBE*W$F+B`J<@A\JX'T&#6/MII:&4IO>U]SJ@VD^'(-@,%G'(V[:/XCZX
MHO1H]W;PZA>&WDBB.8IF/`.>WY52O,Z?XC>^N;66XMY8%CC>./>8R#R,=LTS
M4$:0:7?KI\OV6!F,EJ$&Y<CAMH].OXU3JSNWU&VK.-E9=#1D&DZ_:[Y/(NX8
MCNY.=AQ^E7K>:*XMXY;=P\3#*LO0BL"TC>[U._OX+66WMGMO*`=-IE?UV_I3
MM"O"VCP:;]GNX;@0%-[PE54X]:%5;LF5&6MVM_Q+EY=:+J<HT^\FMYG#\1,W
M\7^-6KF^LM*AC%Q-'`F-J`GT]!7+^6[>'UT8:7.+\87?Y?R!L_ZS?^M7]0BF
ML=9%W/%+-&]J(4FCB\PPN.IV^]3[67*2IOXK:DT^F^'+QH;J6"U?[0^U''`=
MO3CC-:EHUG"[65IY2&`#=%&,;,]*R;2UGU#PS/%J$;*VYFAQ&(V`'*MM'0YJ
MWX;M6@TB.297^TW'[V=I!\Q8^M:*K.=D]ATTE*ZBE<M_V;:?VA]N^SI]JQM\
MW'.,8I;[3;34HU2]MXYE4Y4..AJU15\SO>YKR1LU;<BEMX9X##+$DD1&"C#(
MJA!X:TBVN!-#80K(IR#C.#[`UJ44U.25DQ2IPD[M(****DL****`"BBB@`KG
M_$WA6'78O-B*Q7J#"OV<>C?XUT%)5PG*$N:.YG5I1JQ<)JZ/%+[3[K3+DP7D
M+12#L>A]P>]5J]MN[&VOX3%=P1S1GLXS7-WGP\TV=BUM+/;D]@=R_KS^M>I3
MS"#7OJQX5;**B=Z3NCS:BNY/PU;?\NI#;[P\_P`ZN6OPYL(V!N;J>;_9&$'^
M-;/'45U.>.68ENUK?,\_M[>:[G6&WB>65NBH,DUZ'X6\&C3&6]U#:]V.40<K
M%[^YKH;#2K+2XMEE;QQ`]2HY/U/4U;K@Q&-E47+'1'JX3+(T7SSU?X"T445P
MGJ!1110`E%+10`E%+10`E%+10`E%+10`E+110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
544`%%%%`!1110`4444`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
